Can a combined screening/treatment programme prevent premature failure of renal transplants due to chronic rejection in patients with HLA antibodies: Study protocol for the multicentre randomised controlled OuTSMART trial

Trials

Volumn 15, Issue 1, 2014, Pages

  Dorling, Anthony ^a   Rebollo Mesa, Irene ^a   Hilton, Rachel ^a   Peacock, Janet L ^b   Vaughan, Robert ^a   Gardner, Leanne ^a   Danzi, Guilherme ^a   Baker, Richard ^c   Clark, Brendan ^c   Thuraisingham, Raj C ^d   Buckland, Matthew ^d   Picton, Michael ^e   Martin, Susan ^e   Borrows, Richard ^f   Briggs, David ^g   Horne, Robert ^h   McCrone, Paul ^a   Kelly, Joanna ^b   Murphy, Caroline ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

^e MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^f UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^g NHS BLOOD AND TRANSPLANT   (United Kingdom)

^h UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

biomarker; biomarker led care; blinded; chronic rejection; clinical trial; CTU; diabetes; DSA; EME funded; graft failure; Human leukocyte antigen antibodies; immunosuppression; intention to treat; KCTU; kidney; multicentre; mycophenolate mofetil; NIHR; non DSA; optimised; optimized; per protocol; premature allograft failure; randomised controlled trial; randomized controlled trial; renal transplantation; screening; standard care; tacrolimus; treatment as usual; trials unit; unblinded; usual care

Indexed keywords

BIOLOGICAL MARKER; CREATININE; HLA ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; TACROLIMUS;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER INCIDENCE; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG DOSE TITRATION; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HEALTH ECONOMICS; HUMAN; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; YOUNG ADULT;

BIOLOGICAL MARKERS; CHRONIC DISEASE; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; GREAT BRITAIN; HEALTH CARE COSTS; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892561267     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-30     Document Type: Article

References (42)

1. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011, 11:450-462. 10.1111/j.1600-6143.2010.03283.x, 20973913.
2. Ravanan R, Udayaraj U, Bakran A, Steenkamp R, Williams AJ, Ansell D. Measures of care in adult renal transplant recipients in the United Kingdom (chapter 11). Nephrol Dial Transplant 2007, 22(Suppl 7):vii138-vii154.
3. Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, Gourishankar S, Grande J, Halloran P, Hunsicker L, Mannon R, Rush D, Matas AJ. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010, 90:68-74.
4. Mizutani K, Terasaki P, Rosen A, Esquenazi V, Miller J, Shih RN, Pei R, Ozawa M, Lee J. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005, 5:2265-2272. 10.1111/j.1600-6143.2005.01016.x, 16095508.
5. Lee PC, Zhu L, Terasaki PI, Everly MJ. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009, 88:568-574. 10.1097/TP.0b013e3181b11b72, 19696641.
6. Terasaki PI, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation 2005, 80:1194-1197. 10.1097/01.tp.0000174338.97313.5a, 16314785.
7. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007, 7:408-415. 10.1111/j.1600-6143.2006.01644.x, 17229080.
8. Lachmann N, Terasaki PI, Budde K, Liefeldt L, Kahl A, Reinke P, Pratschke J, Rudolph B, Schmidt D, Salama A, Schonemann C. Anti-human leukocyte antigen and donor-specific antibodies detected by Luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009, 87:1505-1513. 10.1097/TP.0b013e3181a44206, 19461487.
9. van Timmeren MM, Lems SP, Hepkema BG, Bakker SJ. Anti-human leukocyte antigen antibodies and development of graft failure after renal transplantation. Transplantation 2009, 88:1399-1400. 10.1097/TP.0b013e3181bc3ef0, 20029338.
10. Gosho M, Nagashima K, Sato Y. Study designs and statistical analyses for biomarker research. Sensors (Basel) 2012, 12:8966-8986. 10.3390/s120708966, 3444086, 23012528.
11. Mandrekar SJ, Sargent DJ. All-comers versus enrichment design strategy in phase II trials. J Thorac Oncol 2011, 6:658-660. 10.1097/JTO.0b013e31820e17cb, 3082391, 21532916.
12. Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy 2004, 9:197-204. 10.1258/1355819042250249, 15509405.
13. King's Clinical Trials Unit. http://www.ctu.co.uk.
14. Dudley C, Pohanka E, Riad H, Dedochova J, Wijngaard P, Sutter C, Silva HT. Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: the 'creeping creatinine' study. Transplantation 2005, 79:466-475. 10.1097/01.TP.0000151632.21551.00, 15729174.
15. Curtis L. Unit Costs of Health and Social Care 2010 2010, Canterbury: PSSRU, University of Kent.
16. Mora PA, Berkowitz A, Contrada RJ, Wisnivesky J, Horne R, Leventhal H, Halm EA. Factor structure and longitudinal invariance of the Medical Adherence Report Scale - Asthma. Psychol Health 2011, 26:713-727. 10.1080/08870446.2010.490585, 21391132.
17. Cohen JL, Mann DM, Wisnivesky JP, Home R, Leventhal H, Musumeci-Szabo TJ, Halm EA. Assessing the validity of self-reported medication adherence among inner-city asthmatic adults: the Medication Adherence Report Scale for Asthma. Ann Allergy Asthma Immunol 2009, 103:325-331. 10.1016/S1081-1206(10)60532-7, 19852197.
18. Butler JA, Peveler RC, Roderick P, Smith PW, Horne R, Mason JC. Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study. Nephrol Dial Transplant 2004, 19:3144-3149. 10.1093/ndt/gfh505, 15479748.
19. Butler JA, Peveler RC, Roderick P, Horne R, Mason JC. Measuring compliance with drug regimens after renal transplantation: comparison of self-report and clinician rating with electronic monitoring. Transplantation 2004, 77:786-789. 10.1097/01.TP.0000110412.20050.36, 15021850.
20. Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, Mukherjee J. Can simple clinical measurements detect patient noncompliance?. Hypertension 1980, 2:757-764. 10.1161/01.HYP.2.6.757, 7007235.
21. Gordis L. Conceptual and methodologic problems in measuring patient compliance. Compliance in Health Care 1979, 23-45. London: John Hopkins University Press, Sackett DL, Taylor DW, Taylor DW RBH.
22. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999, 14:1-24.
23. Horne R, Hankins M, Jenkins R. The satisfaction with information about medicines scale (SIMS): a new measurement tool for audit and research. Qual Health Care 2001, 10:135-140. 10.1136/qhc.0100135, 1743429, 11533420.
24. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370. 10.1111/j.1600-0447.1983.tb09716.x, 6880820.
25. Moss-Morris R, Weinman J, Petrie KJ, Horne R, Cameron LD, Buick D. The revised illness perception questionnaire (IPQ-R). Psychol Health 2002, 17:1-16.
26. Beatty PC, Willis GB. Research synthesis: the practice of cognitive interviewing. Public Opin Q 2007, 71:287-311.
27. Theruvath TP, Saidman SL, Mauiyyedi S, Delmonico FL, Williams WW, Tolkoff-Rubin N, Collins AB, Colvin RB, Cosimi AB, Pascual M. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 2001, 72:77-83. 10.1097/00007890-200107150-00016, 11468538.
28. Billing H, Rieger S, Ovens J, Susal C, Melk A, Waldherr R, Opelz G, Tonshoff B. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 2008, 86:1214-1221. 10.1097/TP.0b013e3181880b35, 19005402.
29. Fehr T, Rusi B, Fischer A, Hopfer H, Wuthrich RP, Gaspert A. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009, 87:1837-1841. 10.1097/TP.0b013e3181a6bac5, 19543061.
30. Rostaing L, Guilbeau-Frugier C, Fort M, Mekhlati L, Kamar N. Treatment of symptomatic transplant glomerulopathy with rituximab. Transpl Int 2009, 22:906-913. 10.1111/j.1432-2277.2009.00896.x, 19453996.
31. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 1997, 63:39-47. 10.1097/00007890-199701150-00008, 9000658.
32. Sola R, Diaz JM, Guirado L, Sainz Z, Gich I, Picazo M, Garcia R, Abreu E, Ortiz F, Alcaraz A. Tacrolimus in induction immunosuppressive treatment in renal transplantation: comparison with cyclosporine. Transplant Proc 2003, 35:1699-1700. 10.1016/S0041-1345(03)00607-9, 12962763.
33. Ahsan N, Johnson C, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, VanVeldhuisen P, Salm K, Tolzman D, Fitzsimmons WE. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation 2001, 72:245-250. 10.1097/00007890-200107270-00014, 11477347.
34. Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005, 4. CD003961.
35. Lederer SR, Friedrich N, Banas B, Welser G, Albert ED, Sitter T. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation. Clin Transplant 2005, 19:168-174. 10.1111/j.1399-0012.2005.00261.x, 15740551.
36. Van der Mast BJ, van Besouw NM, Witvliet MD, de Kuiper P, Smak Gregoor P, Van Gelder T, Weimar W, Claas FH. Formation of donor-specific human leukocyte antigen antibodies after kidney transplantation: correlation with acute rejection and tapering of immunosuppression. Transplantation 2003, 75:871-877. 10.1097/01.TP.0000054840.70526.D0, 12660517.
37. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, Margreiter R, Hugo C, Grinyo JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007, 357:2562-2575. 10.1056/NEJMoa067411, 18094377.
38. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC, Wolfe RA, Agodoa LY, Kaplan B. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000, 69:2405-2409. 10.1097/00007890-200006150-00033, 10868649.
39. Meier M, Nitschke M, Weidtmann B, Jabs WJ, Wong W, Suefke S, Steinhoff J, Fricke L. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial. Transplantation 2006, 81:1035-1040. 10.1097/01.tp.0000220480.84449.71, 16612281.
40. Meier-Kriesche HU, Merville P, Tedesco-Silva H, Heemann U, Kes P, Haller H, Rostaing L, Gafner N, Bernasconi C. Mycophenolate mofetil initiation in renal transplant patients at different times posttransplantation: the TranCept Switch study. Transplantation 2011, 91:984-990. 10.1097/TP.0b013e3182130966, 21464796.
41. Jevnikar A, Arlen D, Barrett B, Boucher A, Cardella C, Cockfield SM, Rush D, Paraskevas S, Shapiro J, Shoker A, Yilmaz S, Zaltzman JS, Kiberd B. Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. Transplantation 2008, 86:953-960. 10.1097/TP.0b013e318186dd0c, 18852662.
42. Remuzzi G, Cravedi P, Costantini M, Lesti M, Ganeva M, Gherardi G, Ene-Iordache B, Gotti E, Donati D, Salvadori M, Sandrini S, Segoloni G, Federico S, Rigotti P, Sparacino V, Ruggenenti P. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol 2007, 18:1973-1985. 10.1681/ASN.2006101153, 17460145.